Aaron J Grossberg1, Sasikarn Chamchod2, Clifton D Fuller3, Abdallah S R Mohamed4, Jolien Heukelom5, Hillary Eichelberger6, Michael E Kantor1, Katherine A Hutcheson7, G Brandon Gunn3, Adam S Garden3, Steven Frank3, Jack Phan3, Beth Beadle3, Heath D Skinner3, William H Morrison3, David I Rosenthal3. 1. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston. 2. Head and Neck Section, Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston3Radiation Oncology Unit, Chulabhorn Hospital, Bangkok, Thailand. 3. Head and Neck Section, Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston. 4. Head and Neck Section, Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston4Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria, Alexandria, Egypt. 5. Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. 6. currently a medical student at University of Texas Medical School at Houston. 7. Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston.
Abstract
IMPORTANCE: Major weight loss is common in patients with head and neck squamous cell carcinoma (HNSCC) who undergo radiotherapy (RT). How baseline and posttreatment body composition affects outcome is unknown. OBJECTIVE: To determine whether lean body mass before and after RT for HNSCC predicts survival and locoregional control. DESIGN, SETTING, AND PARTICIPANT: Retrospective study of 2840 patients with pathologically proven HNSCC undergoing curative RT at a single academic cancer referral center from October 1, 2003, to August 31, 2013. One hundred ninety patients had computed tomographic (CT) scans available for analysis of skeletal muscle (SM). The effect of pre-RT and post-RT SM depletion (defined as a CT-measured L3 SM index of less than 52.4 cm2/m2 for men and less than 38.5 cm2/m2 for women) on survival and disease control was evaluated. Final follow-up was completed on September 27, 2014, and data were analyzed from October 1, 2014, to November 29, 2015. MAIN OUTCOMES AND MEASURES: Primary outcomes were overall and disease-specific survival and locoregional control. Secondary analyses included the influence of pre-RT body mass index (BMI) and interscan weight loss on survival and recurrence. RESULTS: Among the 2840 consecutive patients who underwent screening, 190 had whole-body positron emission tomography-CT or abdominal CT scans before and after RT and were included for analysis. Of these, 160 (84.2%) were men and 30 (15.8%) were women; their mean (SD) age was 57.7 (9.4) years. Median follow up was 68.6 months. Skeletal muscle depletion was detected in 67 patients (35.3%) before RT and an additional 58 patients (30.5%) after RT. Decreased overall survival was predicted by SM depletion before RT (hazard ratio [HR], 1.92; 95% CI, 1.19-3.11; P = .007) and after RT (HR, 2.03; 95% CI, 1.02-4.24; P = .04). Increased BMI was associated with significantly improved survival (HR per 1-U increase in BMI, 0.91; 95% CI, 0.87-0.96; P < .001). Weight loss without SM depletion did not affect outcomes. Post-RT SM depletion was more substantive in competing multivariate models of mortality risk than weight loss-based metrics (Bayesian information criteria difference, 7.9), but pre-RT BMI demonstrated the greatest prognostic value. CONCLUSIONS AND RELEVANCE: Diminished SM mass assessed by CT imaging or BMI can predict oncologic outcomes for patients with HNSCC, whereas weight loss after RT initiation does not predict SM loss or survival.
IMPORTANCE: Major weight loss is common in patients with head and neck squamous cell carcinoma (HNSCC) who undergo radiotherapy (RT). How baseline and posttreatment body composition affects outcome is unknown. OBJECTIVE: To determine whether lean body mass before and after RT for HNSCC predicts survival and locoregional control. DESIGN, SETTING, AND PARTICIPANT: Retrospective study of 2840 patients with pathologically proven HNSCC undergoing curative RT at a single academic cancer referral center from October 1, 2003, to August 31, 2013. One hundred ninety patients had computed tomographic (CT) scans available for analysis of skeletal muscle (SM). The effect of pre-RT and post-RT SM depletion (defined as a CT-measured L3 SM index of less than 52.4 cm2/m2 for men and less than 38.5 cm2/m2 for women) on survival and disease control was evaluated. Final follow-up was completed on September 27, 2014, and data were analyzed from October 1, 2014, to November 29, 2015. MAIN OUTCOMES AND MEASURES: Primary outcomes were overall and disease-specific survival and locoregional control. Secondary analyses included the influence of pre-RT body mass index (BMI) and interscan weight loss on survival and recurrence. RESULTS: Among the 2840 consecutive patients who underwent screening, 190 had whole-body positron emission tomography-CT or abdominal CT scans before and after RT and were included for analysis. Of these, 160 (84.2%) were men and 30 (15.8%) were women; their mean (SD) age was 57.7 (9.4) years. Median follow up was 68.6 months. Skeletal muscle depletion was detected in 67 patients (35.3%) before RT and an additional 58 patients (30.5%) after RT. Decreased overall survival was predicted by SM depletion before RT (hazard ratio [HR], 1.92; 95% CI, 1.19-3.11; P = .007) and after RT (HR, 2.03; 95% CI, 1.02-4.24; P = .04). Increased BMI was associated with significantly improved survival (HR per 1-U increase in BMI, 0.91; 95% CI, 0.87-0.96; P < .001). Weight loss without SM depletion did not affect outcomes. Post-RT SM depletion was more substantive in competing multivariate models of mortality risk than weight loss-based metrics (Bayesian information criteria difference, 7.9), but pre-RT BMI demonstrated the greatest prognostic value. CONCLUSIONS AND RELEVANCE: Diminished SM mass assessed by CT imaging or BMI can predict oncologic outcomes for patients with HNSCC, whereas weight loss after RT initiation does not predict SM loss or survival.
Authors: Harriët Jager-Wittenaar; Pieter U Dijkstra; Arjan Vissink; Johannes A Langendijk; Bernard F A M van der Laan; Jan Pruim; Jan L N Roodenburg Journal: Head Neck Date: 2010-08-24 Impact factor: 3.147
Authors: Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre Journal: Head Neck Date: 2005-10 Impact factor: 3.147
Authors: Lisa Martin; Laura Birdsell; Neil Macdonald; Tony Reiman; M Thomas Clandinin; Linda J McCargar; Rachel Murphy; Sunita Ghosh; Michael B Sawyer; Vickie E Baracos Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544
Authors: Carla M M Prado; Jessica R Lieffers; Linda J McCargar; Tony Reiman; Michael B Sawyer; Lisa Martin; Vickie E Baracos Journal: Lancet Oncol Date: 2008-06-06 Impact factor: 41.316
Authors: Marina Mourtzakis; Carla M M Prado; Jessica R Lieffers; Tony Reiman; Linda J McCargar; Vickie E Baracos Journal: Appl Physiol Nutr Metab Date: 2008-10 Impact factor: 2.665
Authors: J A E Langius; S Bakker; D H F Rietveld; H M Kruizenga; J A Langendijk; P J M Weijs; C R Leemans Journal: Br J Cancer Date: 2013-08-08 Impact factor: 7.640
Authors: Bette J Caan; Jeffrey A Meyerhardt; Candyce H Kroenke; Stacey Alexeeff; Jingjie Xiao; Erin Weltzien; Elizabeth Cespedes Feliciano; Adrienne L Castillo; Charles P Quesenberry; Marilyn L Kwan; Carla M Prado Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-05-15 Impact factor: 4.254
Authors: Laura W J Baijens; Margaret Walshe; Leena-Maija Aaltonen; Christoph Arens; Reinie Cordier; Patrick Cras; Lise Crevier-Buchman; Chris Curtis; Wojciech Golusinski; Roganie Govender; Jesper Grau Eriksen; Kevin Hansen; Kate Heathcote; Markus M Hess; Sefik Hosal; Jens Peter Klussmann; C René Leemans; Denise MacCarthy; Beatrice Manduchi; Jean-Paul Marie; Reza Nouraei; Claire Parkes; Christina Pflug; Walmari Pilz; Julie Regan; Nathalie Rommel; Antonio Schindler; Annemie M W J Schols; Renee Speyer; Giovanni Succo; Irene Wessel; Anna C H Willemsen; Taner Yilmaz; Pere Clavé Journal: Eur Arch Otorhinolaryngol Date: 2020-12-19 Impact factor: 2.503
Authors: Lucas Stone; Brennan Olson; Alia Mowery; Stephanie Krasnow; Angie Jiang; Ryan Li; Joshua Schindler; Mark K Wax; Peter Andersen; Daniel Marks; Virginie Achim; Daniel Clayburgh Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-07-01 Impact factor: 6.223
Authors: William G Albergotti; Kara S Davis; Shira Abberbock; Julie E Bauman; James Ohr; David A Clump; Dwight E Heron; Umamaheswar Duvvuri; Seungwon Kim; Jonas T Johnson; Robert L Ferris Journal: Oral Oncol Date: 2016-07-07 Impact factor: 5.337
Authors: Ronald Maggiore; Zachary S Zumsteg; Karlynn BrintzenhofeSzoc; Kelly M Trevino; Ajeet Gajra; Beatriz Korc-Grodzicki; Joel B Epstein; Stewart M Bond; Ira Parker; Julie A Kish; Barbara A Murphy; Noam A VanderWalde Journal: Int J Radiat Oncol Biol Phys Date: 2017-07-15 Impact factor: 7.038
Authors: Sasikarn Chamchod; Clifton D Fuller; Abdallah S R Mohamed; Aaron Grossberg; Jay A Messer; Jolien Heukelom; G Brandon Gunn; Micheal E Kantor; Hillary Eichelberger; Adam S Garden; David I Rosenthal Journal: Oral Oncol Date: 2016-08-31 Impact factor: 5.337
Authors: Bárbara Ferrão; Pedro Miguel Neves; Teresa Santos; Manuel Luís Capelas; Antti Mäkitie; Paula Ravasco Journal: Support Care Cancer Date: 2020-06-13 Impact factor: 3.603